This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wittig, R. Articles by Poustka, A. Search for Related Content PubMed PubMed Citation Articles by Wittig, R. Articles by Poustka, A.

Candidate Genes for Cross-Resistance against DNA-damaging Drugs^{1 ,2}

Department of Molecular Genome Analysis [R. W., R. D. W., J. M., R. S., E. M., P. K., A. P.], Department of Molecular Genetics, [M. N., P. L.], and Skin Cancer Unit [H. H., B. G., D. S.], Deutsches Krebsforschungszentrum, and Resource Center for Genome Research [M. S., B. K.], D-69120 Heidelberg, Germany

Drug resistance of tumor cells leads to major drawbacks in the treatment of cancer. To identify candidate genes for drug resistance, we compared the expression patterns of the drug-sensitive human malignant melanoma cell line MeWo and three derived sublines with acquired resistance to the DNA-damaging agents cisplatin, etoposide, and fotemustine. Subarray analyses confirmed 57 candidate genes recovered from a genome-wide scan for differential expression. By specifically addressing cancer genes we retrieved another set of 209 candidates. Exemplary Northern blot studies indicated qualitative concordance for 110 of 135 (81.4%) data points. Whereas the etoposide-resistant line showed constant expression patterns over a period of 2.5 years, the fotemustine- and cisplatin-resistant sublines exhibited considerable variability. Initially representing distinct entities, these two sublines finally converged in their expression patterns. A total of 110 genes was transiently or permanently deregulated in at least two resistant sublines. Fourteen genes displayed differential expression in all three of the sublines. We hypothesize that the variations in fotemustine and cisplatin resistance are based on progressive optimization and/or polyclonality. This, in addition to genomic alterations investigated by comparative genomic hybridization and evaluation of short-term response genes, can be used as a criterion for the selection of promising candidates. Among these are CYR61, AHCYL1, and MPP1, as well as several apoptosis-related genes, in particular STK17A and CRYAB. As MPP1 and CRYAB are also among the 14 genes differentially expressed in all three of the drug-resistant sublines, they represent the strongest candidates for resistance against DNA-damaging drugs.

This article has been cited by other articles:

				R. Ria, K. Todoerti, S. Berardi, A. M. L. Coluccia, A. De Luisi, M. Mattioli, D. Ronchetti, F. Morabito, A. Guarini, M. T. Petrucci, et al. Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma Clin. Cancer Res., September 1, 2009; 15(17): 5369 - 5378. [Abstract] [Full Text] [PDF]

				K. Ridd, S.-D. Zhang, R. E. Edwards, R. Davies, P. Greaves, A. Wolfreys, A. G. Smith, and T. W. Gant Association of gene expression with sequential proliferation, differentiation and tumor formation in murine skin Carcinogenesis, August 1, 2006; 27(8): 1556 - 1566. [Abstract] [Full Text] [PDF]

				C. S. Wilson, G. S. Davidson, S. B. Martin, E. Andries, J. Potter, R. Harvey, K. Ar, Y. Xu, K. J. Kopecky, D. P. Ankerst, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction Blood, July 15, 2006; 108(2): 685 - 696. [Abstract] [Full Text] [PDF]

				A. A. Jazaeri, C. S. Awtrey, G. V.R. Chandramouli, Y. E. Chuang, J. Khan, C. Sotiriou, O. Aprelikova, C. J. Yee, K. K. Zorn, M. J. Birrer, et al. Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers Clin. Cancer Res., September 1, 2005; 11(17): 6300 - 6310. [Abstract] [Full Text] [PDF]

				R. Konig, D. Baldessari, N. Pollet, C. Niehrs, and R. Eils Reliability of gene expression ratios for cDNA microarrays in multiconditional experiments with a reference design Nucleic Acids Res., February 13, 2004; 32(3): e29 - e29. [Abstract] [Full Text] [PDF]